BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

738 related articles for article (PubMed ID: 33946869)

  • 1. Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication.
    Pirzada RH; Haseeb M; Batool M; Kim M; Choi S
    Cells; 2021 Apr; 10(5):. PubMed ID: 33946869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2.
    Jang Y; Shin JS; Lee MK; Jung E; An T; Kim UI; Kim K; Kim M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses
    Stone NE; Jaramillo SA; Jones AN; Vazquez AJ; Martz M; Versluis LM; Raniere MO; Nunnally HE; Zarn KE; Nottingham R; Ng KR; Sahl JW; Wagner DM; Knudsen S; Settles EW; Keim P; French CT
    mBio; 2021 Jan; 12(1):. PubMed ID: 33468703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
    Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
    Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.
    Stegmann KM; Dickmanns A; Gerber S; Nikolova V; Klemke L; Manzini V; Schlösser D; Bierwirth C; Freund J; Sitte M; Lugert R; Salinas G; Meister TL; Pfaender S; Görlich D; Wollnik B; Groß U; Dobbelstein M
    Virus Res; 2021 Sep; 302():198469. PubMed ID: 34090962
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency.
    Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M
    J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective.
    Seifert M; Bera SC; van Nies P; Kirchdoerfer RN; Shannon A; Le TT; Meng X; Xia H; Wood JM; Harris LD; Papini FS; Arnold JJ; Almo S; Grove TL; Shi PY; Xiang Y; Canard B; Depken M; Cameron CE; Dulin D
    Elife; 2021 Oct; 10():. PubMed ID: 34617885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir.
    Pohl MO; Busnadiego I; Marrafino F; Wiedmer L; Hunziker A; Fernbach S; Glas I; Moroz-Omori EV; Hale BG; Caflisch A; Stertz S
    J Gen Virol; 2021 Jul; 102(7):. PubMed ID: 34319869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.
    Bafna K; White K; Harish B; Rosales R; Ramelot TA; Acton TB; Moreno E; Kehrer T; Miorin L; Royer CA; García-Sastre A; Krug RM; Montelione GT
    Cell Rep; 2021 May; 35(7):109133. PubMed ID: 33984267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections.
    Jin YH; Min JS; Jeon S; Lee J; Kim S; Park T; Park D; Jang MS; Park CM; Song JH; Kim HR; Kwon S
    Phytomedicine; 2021 Jun; 86():153440. PubMed ID: 33376043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The
    Urda L; Kreuter MH; Drewe J; Boonen G; Butterweck V; Klimkait T
    Viruses; 2022 Jan; 14(1):. PubMed ID: 35062310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral effects of human placenta hydrolysate (Laennec
    Kim EH; Kim YI; Jang SG; Im M; Jeong K; Choi YK; Han HJ
    J Microbiol; 2021 Nov; 59(11):1056-1062. PubMed ID: 34613605
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Binding Site of Remdesivir and Its Metabolites with NSP12-NSP7-NSP8, and NSP3 of SARS CoV-2 Virus and Alternative Potential Drugs for COVID-19 Treatment.
    Jung LS; Gund TM; Narayan M
    Protein J; 2020 Dec; 39(6):619-630. PubMed ID: 33185784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aurasperone A Inhibits SARS CoV-2 In Vitro: An Integrated In Vitro and In Silico Study.
    ElNaggar MH; Abdelwahab GM; Kutkat O; GabAllah M; Ali MA; El-Metwally MEA; Sayed AM; Abdelmohsen UR; Khalil AT
    Mar Drugs; 2022 Feb; 20(3):. PubMed ID: 35323478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of itraconazole against SARS-CoV-2.
    Van Damme E; De Meyer S; Bojkova D; Ciesek S; Cinatl J; De Jonghe S; Jochmans D; Leyssen P; Buyck C; Neyts J; Van Loock M
    J Med Virol; 2021 Jul; 93(7):4454-4460. PubMed ID: 33666253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.
    Kokic G; Hillen HS; Tegunov D; Dienemann C; Seitz F; Schmitzova J; Farnung L; Siewert A; Höbartner C; Cramer P
    Nat Commun; 2021 Jan; 12(1):279. PubMed ID: 33436624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacologic profiling reveals lapatinib as a novel antiviral against SARS-CoV-2 in vitro.
    Raymonda MH; Ciesla JH; Monaghan M; Leach J; Asantewaa G; Smorodintsev-Schiller LA; Lutz MM; Schafer XL; Takimoto T; Dewhurst S; Munger J; Harris IS
    Virology; 2022 Jan; 566():60-68. PubMed ID: 34871905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
    Zhao J; Guo S; Yi D; Li Q; Ma L; Zhang Y; Wang J; Li X; Guo F; Lin R; Liang C; Liu Z; Cen S
    Antiviral Res; 2021 Jun; 190():105078. PubMed ID: 33894278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir terminated RNA is more resistant to SARS-CoV-2 proofreader than RNA terminated by Remdesivir.
    Jockusch S; Tao C; Li X; Chien M; Kumar S; Morozova I; Kalachikov S; Russo JJ; Ju J
    Sci Rep; 2020 Oct; 10(1):16577. PubMed ID: 33024223
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational Analysis Reveals Monomethylated Triazolopyrimidine as a Novel Inhibitor of SARS-CoV-2 RNA-Dependent RNA Polymerase (RdRp).
    Karthic A; Kesarwani V; Singh RK; Yadav PK; Chaturvedi N; Chauhan P; Yadav BS; Kushwaha SK
    Molecules; 2022 Jan; 27(3):. PubMed ID: 35164069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.